The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the risk of recurrence with adjuvant pembrolizumab compared with placebo. The late breaking results of the KEYNOTE-716 trial are presented at the ESMO Congress 2021.
Changes in individual cancer cells over time may explain why brain tumors develop so differently, and why some cancer cells are resistant to certain treatments. To […]
A team of researchers at the Korea Advanced Institute of Science and Technology, has found a microcircuit in the mouse anterior cingulate cortex (ACC) that appears […]
University of Minnesota Medical School graduate students analyzed and summarized literature on the health effects of chemical demonstration control agents, such as tear gas, including the […]